Table 1. MYO10 expression correlated with clinicopathological and biological factors in 120 breast cancer specimensa.
| Factor | Variable | n (%) | Fold of MYO10 expression (means±s.e.) | P-value |
|---|---|---|---|---|
|
Age |
|
|
|
0.198b |
| ⩽45 | 48 (40.00) | 3.637±0.338 | ||
| 45–60 | 56 (46.67) | 4.198±0.288 | ||
| |
>60 |
16 (13.33) |
4.759±0.678 |
|
|
Size (mm) |
|
|
|
0.069b |
| <20 (stage T1) | 44 (36.67) | 3.663±0.356 | ||
| 20–50 (stage T2) | 63 (52.50) | 4.050±0.285 | ||
| |
⩾50 (stage T3) |
13 (10.83) |
5.349±0.580 |
|
|
ER |
|
|
|
0.000c |
| Positive | 70 (58.33) | 2.934±0.206 | ||
| |
Negative |
50 (41.67) |
5.608±0.304 |
|
|
PR |
|
|
|
0.000c |
| Positive | 68 (56.67) | 2.841±0.203 | ||
| |
Negative |
52 (43.33) |
5.628±0.290 |
|
|
Her2 |
|
|
|
0.521c |
| Positive | 45 (37.50) | 3.872±0.262 | ||
| |
Negative |
75 (62.50) |
4.154±0.300 |
|
|
Luminal A vs B |
|
|
|
0.227c |
| A (ER+, PR+, Her2–, Ki-67 <14%) | 22 (18.33) | 3.238±0.400 | ||
| |
B (ER+, PR+, Her2–, Ki-67 ⩾14% or ER+, PR+, Her2+) |
47 (39.17) |
2.708±0.232 |
|
|
Her2 subtyped |
|
|
|
0.000c |
| |
ER–, PR–, Her2+ |
31 (25.83) |
4.523±0.291 |
|
|
Triple negative (ER–, PR–, Her2–) |
|
|
|
0.000c |
| Yes | 20 (16.67) | 7.354±0.350 | ||
| |
No |
100 (83.33) |
3.387±0.183 |
|
|
Tumour differentiation grade |
|
|
|
0.000c |
| Grade 1/2 | 75 (62.50) | 2.883±0.200 | ||
| |
Grade 3 |
45 (37.50) |
5.990±0.271 |
|
|
Lymph node metastasis |
|
|
|
0.002c |
| No (N–) | 49 (40.83) | 3.255±0.361 | ||
| Yes (N+) | 71 (59.17) | 4.596±0.238 |
a
Fold of MYO10 expression (GAPDH as control) in breast cancer tissue over adjacent nonmalignant tissue from the same specimen. Triple repeated per specimen.
b
One-way ANOVA.
c
Independent t-test.
d
Compared with luminal A and B.